OR WAIT null SECS
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 2, 2022.
The approvals were based on results from the JUNIPERA trial, which showed secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA.
"The challenges of an existing rheumatologist workforce shortage, changing workforce demographics, and physician burnout have been compounded by the COVID-19 pandemic."
Take a few minutes to discover Rheumatology Network's most-viewed EULAR 2022 coverage.
The Committee for Medicinal Products for Human Use (CHMP) recommends approving upadacitinib 15 mg, once daily, for the treatment of active non-radiographic axial spondyloarthritis in adults patients with inflammation and inadequate response to NSAIDs.
The approval and implementation of new drugs can vastly improve quality of life and reduce signs and symptoms of disease burden in patients with rheumatic and dermatologic diseases.